Retired CFO
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And if Arete is telling you the taxes for 2009 have been paid then just call the number on the website, (307)682-7266, and ask them. Just give them the property ID 42236. They are very friendly. I hope after you're convinced you will post what you find. Thanks.
Mr Long, just give them two months. If we aren't doing much better by year-end then you can sell. Stick with us a little while longer.
Hey Wildcatter. I've given out this address before but here it is again. Put in Arete Industries for the company name. Then click on tax detail and change the year to 2009. One payment was due Nov 10, 2009 and the other May 10, 2010. Neither has been paid.
http://www.ccgov.net/assessor/online/
Actually I did Gruber. But not any longer. I'm told Matt has talked about the new bag on the Corcell site but I haven't looked to see. I have no clue what is coming but I'm excited.
Agent, I expect more than one acquisition before year-end. I really have no clue what the big news is but it's coming I have no doubt. And I think by year-end. If the company in Mexico is the one I think we're buying that's a pretty big deal. But it's not the big deal. Whatever it is, I expect it to actually knock us all over with a feather. As Matt said in his response to CBAIWaiting, he doesn't boast unless he knows he can deliver. I can't wait. Mainly so Pitman will stop complaining. LOL
I agree. Always interested to see the quarterly reports but that's not what is going to get us close to .03. Tick tock.
Mr Vegas, wasn't it you that tried to post a picture of CBAI HQ's this past weekend and said there was a bunch of yellow tape around the parking lot? The reason for that is Matt lets the Church use his parking lot on Sundays. No big deal.
Hey Pitman, I went out on a limb and said I think we have a shot of having a ahare price of .03 by year-end. You have been suggesting regularly that Matt is still diluting. The last report had the shares at 5.3B. If dilution is still going on as you suggest give us a figure you think the shares will be at in the next 10Q. Just for fun. We only have about two weeks and we'll know for sure.
Yeah. He said for Pittman and CBAI Waiting to sell.
You're correct. On November 10th they will be one year past due. Unreal.
Come on people. We already have many of the answers. Who cares if they sell some shares of the new company. We still get our 10% ownership period. We know some of the players. Us, AXMP, and Golden Meditech (but under a shell also). Just wait for the announcement and I think we will be pleased. The faster they grow the more royalties we get. So if they issue and sell shares that won't dilute our 10% but it will help them raise cash to grow quickly. Chill.
This is just our shell company where China revs will flow. I expect the new China sub to come out with an announcement before year-end and that is where we will get guidance on the new company and where they want to take it. Remember, we only own 10% of that company so have little control over the announcement of that entity. But it's coming soon IMO.
Don't be. Just stay positive for two more months and then lets see how everyone feels. Matt can't give us news until deals are signed. He's made it as clear as he can that big news is coming. And Matt isn't one to lie. I have zero concern here and still believe we have a shot at .03 by year-end.
I only know what was said on the show and did a google search. Viacord has the rights currently. And if you read the article it specifically states that the bag can be used for either a normal birth or a C-Section. Sounds the same to me. Merger?
Like I suggested earlier, I think this new bag being used is interesting. It's been out since 2006 but we're now just starting to use it. Why?
First FDA Clearance of Sterile Field Cord Blood Collection Bag
ViaCell and Pall Announce Collaborative Agreement
East Hills, NY and Cambridge, MA (April 25, 2006) -- ViaCell, Inc. (NASDAQ: VIAC) and Pall Corporation (NYSE: PLL) announced today the first U.S. Food and Drug Administration clearance of a cord blood collection bag suitable for use in a sterile field. Pall and ViaCell collaborated on the development and design of the new collection bag. ViaCell has exclusive rights to the new collection bag for family cord blood banking and expects to introduce it as part of its ViaCord® collection kit. The new sterile field bag will give families and their health care providers the ability to more safely and easily collect umbilical cord blood from newborns, even when born by cesarean section.
Umbilical cord blood is a valuable source of stem cells used to treat more than 40 life threatening diseases including a wide range of cancers, immune deficiencies and genetic disorders. Collection of cord blood is a critical first step in the process of preserving a baby's umbilical cord blood to meet these and other future medical needs. It is important that the collection kit simply and aseptically collect as much blood as possible since larger units for cord blood generally produce more viable stem cells.
“I believe the new ViaCord collection bag provides a significant benefit to the obstetrician,” said Yoni Branhard, M.D., Vice Chairman of the OB-GYN Department, Lenox Hill Hospital, New York City. “This is an innovative initiative in cord blood banking. The sterile bag gives my colleagues and me the comfort that, no matter how we deliver a child – vaginally or by cesarean - we are collecting the cord blood in a high quality manner.”
Collecting blood from the umbilical cord of babies born by cesarean section, unlike vaginal births, must be done in a sterile surgical field. There are about 1.2 million cesarean sections performed in the U.S. each year, representing about 30 percent of all births. Since not all cesarean births are planned, ViaCell intends to include the new sterile field bag in its ViaCord collection kit provided to all expectant families who decide to preserve their baby's umbilical cord blood. Expectant parents and medical professionals will then have the optimal tools to collect their infant's cord blood, no matter the type of birthing situation.
Karen A. Foster, Vice President, ViaCord Processing Laboratory, said, "We are excited by our collaboration with Pall in developing this innovative bag that allows us to continue offering families the highest quality product. This is a significant development in cord blood collection and further demonstrates our commitment and ability to lead technological advancements in cord blood banking.”
"Our agreement with ViaCell is another milestone in Pall's development and customization of tools to help make cell therapy routine, safe and simple," says Judy Angelbeck, PhD, Senior Vice President, Pall New Technologies. "We are proud to work with ViaCell as they are committed to the highest standards of cord blood collection, processing and storage for family cord blood banking."
Pall products are used by many of the leading cord blood transplant centers in the U.S. and its collection sets were used in the landmark Cord Blood Transplantation (COBLT) study which defines the standards on the use of stem cells from umbilical cord blood.
About Pall Corporation
Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world. Visit Pall at www.pall.com.
About ViaCell, Inc.
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell's Reproductive Health Business commercializes ViaCord®, a product that offers expecting families the option of preserving their baby's umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyteSM, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore. Additional information about ViaCell is available online at http://www.viacellinc.com.
This press release contains forward-looking statements regarding the planned introduction by ViaCell of a new sterile field collection bag and the potential advantages of such a bag. Such statements are based on management's current expectations. The introduction and market acceptance of a new collection bag is subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the Company’s current expectations include, but are not limited to, unexpected delays or clinical or technical hurdles related to the use or supply of the new collection bag or unexpected data related to processing of cord blood using the bag. For more information on the risks and uncertainties associated with ViaCell and its products and programs, see the factors set forth under the heading "Risk Factors That May Affect Results" in the Company's report on Form 10-K for the year ending December 31, 2005, which is on file with the Securities and Exchange Commission. ViaCell does not undertake any obligation to update forward-looking statements.
ViaCord® and ViaCell® are federally registered trademarks and ViaCyteSM is a service mark of ViaCell, Inc.
Actually, I think Necktoeye hit it straight on saying it was more about stem cells and Dr Geoff than about the company. And I thought the host asked some great questions.
Or perhaps there will be a lot more to talk about by the time of the next show. The 10Q will have been released by then and hopefully some good news.
The host said at the beginning of todays show that the subject was stem cells with Dr Geoff and not about CBAI the company. On November 22nd Matt is going to be on the show again and at that time the company will be the focus.
I think what he said was they have recently started using new sterile bags (I took it to mean for all collections) and with the new bags they no longer needed to add something else for C-sections. Dr Geoff brought it up and not Matt. Perhaps Matt wasn't ready to disclose yet? Don't know.
I know very little about them which is why I asked ML. He said these were new "sterile bags".
Stock Analyzer has highlighted CBAI for tomorrow.
CBAI if we can break $.0043 then we could see a return to the previous highs for August which were $.0054 and $.0056
Did you hear the show? Sounds like we are in the middle of changing the stem bags we use. Does that fit with some of your thinking?
True. I think the guys is asking some good questions. We'll see if it generates more volume tomorrow or not.
Here's some news IMO. Matt is on the show today but the subject is stem cells and not really CBAI. But Matt is going to be on the show Nov 22nd to talk about CBAI (I think that is what was said). Perhaps after a big announcement? I'd like to think so.
The reason Ccell is only trading at 5 times mulitple is this is the first quarter they have had that level of earnings per share.
Forget the Revs. Focus on the profitability. The Revs will grow exponentially.
Hello All. I think the acquisitions are only going to multiply from here out. CBR is #1 in the US and the World with 300K stems. But they don't have much of a worldwide presents like we do. I predict by the end of 2012 we will be #1 in the World. And very close to that by the end of this year. Have a great week all.
Bids are stacking and only one on the ask now not VFIN or Nite. We're going up IMO.
I totally agree with your thinking. And if Matt is going to talk about public banking on Monday that fits in perfect.
Could it be a "quiet period"?
Don't have a link but I think Matt said politicians didn't he? If true, it wouldn't be the FDA.
We don't have the volume to suggest something is up though.
Matt has been talking up public storage and grants lately. He rarely says anything by accident. Here is a recent statement on FB.
"Matt Schissler. More samples helps everyone. Govt funding helps build an inventory that the private sector doesn't have. there is room for both, just like public and private schools."
I saw that. Very very sad. Lets all pray stem cells work miracles for this dreaded injury.
I don't think it's the FDA. There are really two questions before us. One, does President Obama visit our facility tomorrow. And the other is are we getting a grant. I don't know about Obama but I do think we are getting a grant and for it to do any good it will have to happen soon. Not only is Harry Reid in a bitter fight to keep his job but so is Congresswoman Dina Titus, also a Democrat from Vegas. They both could use some help and soon.
Cryo-Cell de México SA de CVINTERNET: www.cryo-cell.com.mx
PHONE: +52 (33) 3648-2250 or 01-800-999-CRYO del interior
OFFICE: Guadalajara
STORAGE: Guadalajara
COMMENTS:
Cryo-Cell de México licenses their name and training from the American bank Cryo-Cell, but they are independently owned and have operated their own laboratory in Guadalajara since February 2002.
SERVICES & DISCOUNT OPTIONS:
•List of transplants from laboratory of Cryo-Cell de México (outlined in red)
•News report on spring 2004 transplant performed by Cryo-Cell de México.
•Cryo-Cell de México has operated their own laboratory in Guadalajara since Feb. 2002.
•In summer 2005, and again in 2009, Cryo-Cell de México moved into a bigger building with a secure bunker for long term storage. The current facility has a capacity of 350 million collections, the largest capacity installed in Latino America.
•Cryo-Cell México is accredited by the Ministry of health in México, and by the COFEPRIS (Federal Commission of the Prevention of Health Risks).
•Cryo-Cell México collection kit provides a bag to collect blood from the umbilical cord by gravity drip before delivery of the placenta.
•Cryo-Cell México shipping container holds a temperature logger that can be programmed by the user: the user selects the frequency of temperature readings and the alarm thresholds. It has an LED status indicator and a lithium battery with a lifetime of approx. one year.
•Courier service is not included in the contract, but Cryo-Cell México has relationships with courier providers throughout the country and can help parents hire courier service at a good rate.
•Cryo-Cell Méxicooffers two different options for laboratory processing:
•The first processing option is manual processing by technicians who add a freezing solvent to the blood and spin it in a centrifuge to separate the cell layers. The final storage is in 2 cryogenic vials of sample plus 2 vials for quality control testing.
•The second processing option is automated processing with the Sepax system from the Swiss company Biosafe. Sepax is an automated cell separation system which relies on a light beam to sense the density gradient between different cell layers after the blood has been spun in a centrifuge. The bag kit is sterile, functionally closed, and single-use.
•The final collection is tested for the total MonoNuclear Cell (MNC) count and the CD34+ cell count. These are tests that are correlated with the number of stem cells.
•Final cell storage is in the vapor phase of liquid nitrogen. Separate freezers hold vials from manual processing or bags from automated processing.
•At present (June 2010) the processing fees are $975 manual or $1195 automated. In both cases the first year of storage is included. Thereafter storage is $126/year.
•Payment plans are available, and discounts are offered for packages of pre-paid storage.
•Medical professionals qualify for special rates.
•Cryo-Cell México offers nationwide service and has strategic alliances with numerous hospitals.
•Cryo-Cell México has a charity program to help families with sick children.
•As of June 2010, Cryo-Cell México claims an inventory of more than 63,000 cord blood collections and has released 11 transplants.
Hey Karen. Almost out of posts for today. A merger requires the reallocation of ownership equity. But I've never heard it called a reverse split.
Here is a tidbit of information that you will find interesting. Matt did some PR work for Cryo-Cell when he lived in Tampa and that is how he got the idea to start his own cord blood company.
Of course Joe Vicente the COO and Dr Geoff lived in Tampa then also.
Eric, I don't really know. I haven't done merger work since college but I believe that could take care of both at the same time. So that is my bet. And I think it's someone larger than Cryo-Cell. We may buy them too but not yet.
I think the target is someone bigger.
Personally, I don't think Cryo-Cell is a target. But it's just my opinion.